Table 2.

Recruiting clinical trials combining immunotherapies with other treatment modalities (https://clinicaltrials.gov) * in adult patients (>18 years of age) with sarcoma.

Trial Registration Number	Title
Immunotherapy with radiation therapy
NCT03307616	Nivolumab with and without ipilimumab and radiation therapy in treating patients with recurrent or resectable undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma before surgery
NCT03116529	Neoadjuvant durvalumab and tremelimumab plus radiation for high-risk STS (NEXIS)
NCT03463408	Immunotherapy (ipilimumab and nivolumab) and radiation in resectable STS
NCT03548428	Stereotactic body radiation therapy (SBRT) and atezolizumab versus SBRT (STEREOSARC)
Immunotherapy with chemotherapy
NCT03899805	A phase II study of eribulin and pembrolizumab in STS
NCT03138161	SAINT: Trabectedin, ipilimumab and nivolumab as first line treatment for advanced STS
NCT03074318	Avelumab and trabectedin in treating patients with liposarcoma or leiomyosarcoma that is metastatic or cannot be removed by surgery
NCT03719430	APX005M and doxorubicin in advanced sarcoma
Immunotherapy with targeted therapy
NCT04025931	A single-arm, open, phase II study of chidamide combined with toripalimab (anti-PD1) in refractory and advanced STS
NCT03190174	Nivolumab and ABI-009 (nab-rapamycin)

* As per 22nd of November 2020.